UY35211A - Compuestos tricíclicos - Google Patents
Compuestos tricíclicosInfo
- Publication number
- UY35211A UY35211A UY0001035211A UY35211A UY35211A UY 35211 A UY35211 A UY 35211A UY 0001035211 A UY0001035211 A UY 0001035211A UY 35211 A UY35211 A UY 35211A UY 35211 A UY35211 A UY 35211A
- Authority
- UY
- Uruguay
- Prior art keywords
- tricyclic compounds
- present
- provides
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739335P | 2012-12-19 | 2012-12-19 | |
| US201361906141P | 2013-11-19 | 2013-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35211A true UY35211A (es) | 2014-07-31 |
Family
ID=50030372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035211A UY35211A (es) | 2012-12-19 | 2013-12-19 | Compuestos tricíclicos |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20140171417A1 (zh) |
| EP (1) | EP2935278B1 (zh) |
| JP (1) | JP6284546B2 (zh) |
| KR (1) | KR20150097660A (zh) |
| CN (1) | CN105143230B (zh) |
| AP (1) | AP2015008539A0 (zh) |
| AR (1) | AR094122A1 (zh) |
| AU (1) | AU2013365739A1 (zh) |
| BR (1) | BR112015014292A2 (zh) |
| CA (1) | CA2895660A1 (zh) |
| CL (1) | CL2015001730A1 (zh) |
| CR (1) | CR20150325A (zh) |
| CU (1) | CU20150066A7 (zh) |
| EA (1) | EA201591177A1 (zh) |
| ES (1) | ES2628369T3 (zh) |
| HK (1) | HK1209741A1 (zh) |
| IL (1) | IL239389A0 (zh) |
| MX (1) | MX2015007939A (zh) |
| PE (1) | PE20151055A1 (zh) |
| PH (1) | PH12015501386A1 (zh) |
| SG (1) | SG11201504594QA (zh) |
| TN (1) | TN2015000279A1 (zh) |
| TW (1) | TW201429974A (zh) |
| UY (1) | UY35211A (zh) |
| WO (1) | WO2014097148A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| ES2628369T3 (es) | 2012-12-19 | 2017-08-02 | Novartis Ag | Compuestos tricíclicos para inhibir el canal CFTR |
| EP2935277B1 (en) * | 2012-12-19 | 2017-08-30 | Novartis AG | Tricyclic compounds as cftr inhibitors |
| CN106715536B (zh) * | 2014-09-19 | 2021-06-01 | 莫门蒂夫性能材料股份有限公司 | 用于受控的硅氧烷交联的铂(ii)二烯配合物 |
| CN106478558B (zh) * | 2016-10-17 | 2019-03-29 | 天津雅奥科技发展有限公司 | 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法 |
| IL307863A (en) | 2021-04-29 | 2023-12-01 | Novartis Ag | Diubiquitinase-directed chimeras and related methods |
| CN117654560B (zh) * | 2023-12-01 | 2024-06-04 | 安徽泽升科技股份有限公司 | 一种通过氧化氨基连续化制备硝基化合物的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60025616T2 (de) | 1999-08-25 | 2006-11-30 | Banyu Pharmaceutical Co., Ltd. | Isoindolderivate |
| JP2002255967A (ja) | 2001-02-27 | 2002-09-11 | Banyu Pharmaceut Co Ltd | イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。 |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP2010512389A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
| US20110015137A1 (en) * | 2007-07-05 | 2011-01-20 | Trustees Of Boston University | Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| CA2769847C (en) * | 2009-08-10 | 2019-01-08 | The Regents Of The University Of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| USRE48842E1 (en) * | 2011-05-27 | 2021-12-07 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| ES2628369T3 (es) | 2012-12-19 | 2017-08-02 | Novartis Ag | Compuestos tricíclicos para inhibir el canal CFTR |
| EP2935277B1 (en) * | 2012-12-19 | 2017-08-30 | Novartis AG | Tricyclic compounds as cftr inhibitors |
-
2013
- 2013-12-17 ES ES13826625.9T patent/ES2628369T3/es active Active
- 2013-12-17 WO PCT/IB2013/061043 patent/WO2014097148A1/en active Application Filing
- 2013-12-17 AU AU2013365739A patent/AU2013365739A1/en not_active Abandoned
- 2013-12-17 CN CN201380073218.3A patent/CN105143230B/zh active Active
- 2013-12-17 US US14/109,922 patent/US20140171417A1/en not_active Abandoned
- 2013-12-17 SG SG11201504594QA patent/SG11201504594QA/en unknown
- 2013-12-17 EP EP13826625.9A patent/EP2935278B1/en active Active
- 2013-12-17 CA CA2895660A patent/CA2895660A1/en not_active Abandoned
- 2013-12-17 MX MX2015007939A patent/MX2015007939A/es unknown
- 2013-12-17 BR BR112015014292A patent/BR112015014292A2/pt not_active IP Right Cessation
- 2013-12-17 PE PE2015001056A patent/PE20151055A1/es not_active Application Discontinuation
- 2013-12-17 AP AP2015008539A patent/AP2015008539A0/xx unknown
- 2013-12-17 EA EA201591177A patent/EA201591177A1/ru unknown
- 2013-12-17 US US14/653,084 patent/US9359381B2/en active Active
- 2013-12-17 KR KR1020157019061A patent/KR20150097660A/ko not_active Application Discontinuation
- 2013-12-17 JP JP2015548837A patent/JP6284546B2/ja active Active
- 2013-12-18 TW TW102147023A patent/TW201429974A/zh unknown
- 2013-12-19 AR ARP130104861A patent/AR094122A1/es unknown
- 2013-12-19 UY UY0001035211A patent/UY35211A/es not_active Application Discontinuation
-
2015
- 2015-06-11 IL IL239389A patent/IL239389A0/en unknown
- 2015-06-16 TN TNP2015000279A patent/TN2015000279A1/fr unknown
- 2015-06-17 PH PH12015501386A patent/PH12015501386A1/en unknown
- 2015-06-18 CL CL2015001730A patent/CL2015001730A1/es unknown
- 2015-06-19 CU CUP2015000066A patent/CU20150066A7/es unknown
- 2015-06-19 CR CR20150325A patent/CR20150325A/es unknown
- 2015-10-28 HK HK15110599.7A patent/HK1209741A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015001730A1 (es) | 2015-08-28 |
| IL239389A0 (en) | 2015-07-30 |
| US9359381B2 (en) | 2016-06-07 |
| AP2015008539A0 (en) | 2015-06-30 |
| CR20150325A (es) | 2015-08-10 |
| CN105143230A (zh) | 2015-12-09 |
| PH12015501386A1 (en) | 2015-09-02 |
| TW201429974A (zh) | 2014-08-01 |
| KR20150097660A (ko) | 2015-08-26 |
| EP2935278B1 (en) | 2017-03-15 |
| HK1209741A1 (zh) | 2016-04-08 |
| WO2014097148A9 (en) | 2015-02-19 |
| AR094122A1 (es) | 2015-07-08 |
| SG11201504594QA (en) | 2015-07-30 |
| AU2013365739A1 (en) | 2015-07-09 |
| BR112015014292A2 (pt) | 2017-07-11 |
| TN2015000279A1 (en) | 2016-10-03 |
| CN105143230B (zh) | 2017-06-09 |
| ES2628369T3 (es) | 2017-08-02 |
| WO2014097148A1 (en) | 2014-06-26 |
| PE20151055A1 (es) | 2015-08-05 |
| CA2895660A1 (en) | 2014-06-26 |
| US20140171417A1 (en) | 2014-06-19 |
| JP6284546B2 (ja) | 2018-02-28 |
| EA201591177A1 (ru) | 2015-11-30 |
| JP2016509579A (ja) | 2016-03-31 |
| US20150336986A1 (en) | 2015-11-26 |
| EP2935278A1 (en) | 2015-10-28 |
| CU20150066A7 (es) | 2015-11-27 |
| MX2015007939A (es) | 2016-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| UY35211A (es) | Compuestos tricíclicos | |
| SV2016005351A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| UY35209A (es) | Compuestos tricíclicos | |
| CU20130094A7 (es) | Moduladores de la vía del complemento | |
| CO6781541A2 (es) | Derivados glucósidos y usos de los mismos | |
| EA201590118A1 (ru) | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| IN2015DN00185A (zh) | ||
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| CR20140508A (es) | Moduladores de la ruta del complemento y usos de los mismos | |
| UY35325A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| UY36124A (es) | Derivados de carboxamida | |
| UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| GT201400042A (es) | Compuesto de benzotiazolona | |
| UY33806A (es) | ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7? | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
| UY33857A (es) | Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos. | |
| CU20160170A7 (es) | Derivados de carboxamida | |
| UY35792A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20210715 |